Posted by Michael Wonder on 29 Mar 2022
Seqirus receives Health Canada approval for expanded age indication of its cell-based quadrivalent influenza vaccine for people as young as six months
28 March 2022 - Seqirus announced today that it has received Health Canada approval of Flucelvax Quad (influenza vaccine), its cell-based quadrivalent influenza vaccine for an expanded age indication for children as young as six months old.
With this approval, Flucelvax Quad, the first cell-based influenza vaccine available in Canada, is now indicated for everyone eligible to receive an influenza vaccine in Canada.
